How will new medications affect the lipoprotein apheresis situation in Germany?
Regular lipid apheresis is a treatment modality for patients with severe drug resistant LDL-hypercholesterolemia or lipoprotein(a) elevation and premature atherosclerosis. A number of new approaches is currently being developed which can significantly decrease LDL-cholesterol levels alone or in combination with statins. If proven to be safe, these drugs may significantly reduce the necessity for regular lipid apheresis since more patients will achieve LDL-cholesterol treatment targets by drug therapy alone.
Medical Department II, Grosshadern, University Munich, Marchioninistraße 15, 81377 Munich, Germany. klaus.parhofer@med.uni-muenchen.de
K G
KG
Parhofer
D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000009:adverse effects; D008078:Cholesterol, LDL / Q000097:blood; D005858:Germany; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D016896:Treatment Outcome
D015415:Biomarkers; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D008074:Lipoproteins